Did liothyronine treatment have any impact on clinical measures of disability in MS patients?
Label:chem
Topic
Assessing the impact of liothyronine on clinical measures of disability is crucial to understanding its potential therapeutic benefits in MS.
From: "A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS", Neurotherapeutics, Volume 20, Issue 5, September 2023, Pages 1263-1274
Answer
The study found that the Expanded Disability Status Scale (EDSS) remained stable throughout the study. There were no significant changes in other clinical measures such as the Symbol Digit Modalities Test (SDMT), Multiple Sclerosis Functional Composite (MSFC), Functional Assessment of Multiple Sclerosis (FAMS), or Mood 24/7. However, a slight improvement in the timed 25-foot walk test (T25FW) was observed in progressive MS patients, and a trend for improved thinking/fatigue was noted in relapsing MS patients.
Return to Home
Chemical List
Knowledge you may be interested in